The world of biosimilar litigation is back in full swing with several BPCIA lawsuits currently pending. On October 12, 2023, in the second webinar in Goodwin’s 2023 Biosimilars Webinar Series, Goodwin IP Litigation partner and BMW Founding Editor, Elaine Blais, Goodwin IP Litigation partner and BMW Editor-in-Chief, Natasha Daughtrey and Goodwin IP Litigation partner and BMW editor, Alexandra Valenti, will analyze strategies and considerations during pre-litigation disclosures under the BPCIA (the so-called “patent dance”) and in BPCIA litigation with a particular focus on what they have learned from the most recent wave of BPCIA litigations. They will discuss considerations for the timing of filing an aBLA, strategies for disclosure during the patent dance and early litigation and key issues during BPCIA litigation from the perspectives of a reference product sponsor and a biosimilar applicant.
Click here to register for the webinar.
CLE credit will be offered for California, Minnesota, New Jersey, New York and Pennsylvania.